Lipoxins

Trihydroxy derivatives of eicosanoic acids. They are primarily derived from arachidonic acid, however eicosapentaenoic acid derivatives also exist. Many of them are naturally occurring mediators of immune regulation.

Also Known As:

Networked: 529 relevant articles (30 outcomes, 36 trials/studies)

Relationship Network

Bio-Agent Context: Research Results

Experts

1.	Serhan, Charles N: 45 articles (01/2022 - 01/2002)
2.	Das, Undurti N: 30 articles (01/2020 - 07/2005)
3.	Godson, Catherine: 22 articles (01/2021 - 06/2002)
4.	Levy, Bruce D: 15 articles (01/2016 - 09/2002)
5.	Chiang, Nan: 11 articles (01/2019 - 01/2002)
6.	Serhan, C N: 11 articles (01/2019 - 01/2000)
7.	Börgeson, Emma: 9 articles (07/2022 - 07/2010)
8.	Van Dyke, Thomas E: 9 articles (12/2017 - 01/2003)
9.	Shang, You: 9 articles (02/2016 - 04/2010)
10.	Wu, Sheng-Hua: 8 articles (04/2017 - 03/2007)

Related Diseases

1.	Inflammation (Inflammations) 09/14/2022 - "Finally, new pharmacological insights into the management of chronic inflammation addressing the resolution of inflammation based on pro-resolving mediators, such as lipoxin, maresin, and resolvins, examining their biosynthesis, biological properties, and pharmacokinetic and pharmaceuticals limitations, are given. " 12/15/2016 - "The efficacy of lipoxins and their analog epilipoxins in treating inflammation and its associated diseases has been well documented. " 07/15/2022 - "Using explant cultures, this study provides the first proof-of-concept evidence supporting the therapeutic potential of lipoxins in reducing human adipose tissue inflammation. " 02/01/2012 - "Temporal-metabolomic studies of local mediators during inflammation and its resolution uncovered novel pathways and mediators, e.g., lipoxins, resolvins, and protectins that stimulate key resolution responses. " 08/01/2011 - "In this study, we aimed to investigate the expression and potential role of lipoxin A(4) and FPR2/ALX in the regulation of inflammation associated with cyclical remodeling of the human endometrium across the menstrual cycle and during early pregnancy. "
2.	Infections 01/01/2015 - "Lipoxin Inhibits Fungal Uptake by Macrophages and Reduces the Severity of Acute Pulmonary Infection Caused by Paracoccidioides brasiliensis." 10/01/2008 - "Role of lipoxin in the modulation of immune response during infection." 09/01/2005 - "Lipoxins play a key role in controlling potent pro-inflammatory responses triggered by infection with pathogens, such as Toxoplasma gondii and Mycobacterium tuberculosis. " 01/01/2023 - "Upregulation of lipoxins is effective in counteracting inflammation and infection. " 04/01/2015 - "Given the link between intrauterine infection and inflammation and preterm labour (PTL), we hypothesized that administration of lipoxins, key anti-inflammatory and pro-resolution mediators, could be a useful novel treatment for PTL. "
3.	Pain (Aches) 01/01/2020 - "Specialized pro-resolving mediators (SPM): lipoxins, resolvins, protectins and maresins, are potent endogenous molecules (nM concentrations) that modulate inflammatory body responses by reducing neutrophil infiltration, macrophage activity and pain sensitization. " 02/19/2007 - "The antiinflammatory role of peripheral lipoxins raises the hypothesis that similar neuraxial systems may also down-regulate injury-induced spinal facilitation of pain processing. " 01/01/2013 - "The inhibitory effect of lipoxins and resolvins on spinal nociceptive processing puts them in an intriguing position in the search for novel pain therapeutics. " 02/19/2007 - "We report that the lipoxin A(4) receptor is expressed on spinal astrocytes both in vivo and in vitro and that spinal delivery of lipoxin A(4), as well as stable analogues, attenuates inflammation-induced pain. " 09/01/2021 - "SPMs include the ω-3-derived family of molecules, such as resolvins, protectins, and maresins, as well as arachidonic acid-derived (ω-6) lipoxins that stimulate and promote resolution of inflammation, clearance of microbes, and alleviation of pain and promote tissue regeneration via novel mechanisms. "
4.	Pancreatitis 04/10/2012 - "[Protective effects and possible mechanism of lipoxin A(4) analogue in rats with acute pancreatitis]." 04/10/2012 - "To explore the protective effects and possible mechanism of lipoxin A(4)-methyl ester (LXA(4)-ME) in rats with acute pancreatitis (AP). " 02/01/2011 - "Our aim was to investigate the protective effects of a Lipoxin A(4) analogue (LXA4) in the early phase of acute pancreatitis in rats. " 04/01/2014 - "BML-111, a lipoxin receptor agonist, ameliorates 'two-hit'-induced acute pancreatitis-associated lung injury in mice by the upregulation of heme oxygenase-1."
5.	Neoplasms (Cancer) 01/01/2012 - "Thus, methods designed to enhance endogenous lipoxin A(4) formation or its synthetic analogs may be useful in the management of cancer." 01/01/2019 - "Objective: In this study, we have investigated in vivo the cellular mechanisms underlying the anti-tumor property of lipoxins. " 10/01/2019 - "The role of lipoxin in regulating tumor immune microenvironments." 01/01/2019 - "Lipoxin-Induced Phenotypic Changes in CD115+LY6Chi Monocytes TAM Precursors Inhibits Tumor Development." 01/15/2017 - "Together, the results show an unexpected effect of lipoxin, which induces in TAM a change from an M2- to an M1-like profile, thereby triggering tumor cell apoptosis and down-modulating the tumor progression."

Related Drugs and Biologics

1.	methyl ester 5(S),6(R)-7-trihydroxyheptanoic acid
2.	Lipids
3.	lipoxin A4
4.	Aspirin (Acetylsalicylic Acid)
5.	Arachidonic Acid (Vitamin F)
6.	Cytokines
7.	Esters
8.	Heme Oxygenase-1
9.	Leukotrienes
10.	Eicosanoids

Related Therapies and Procedures

1.	Therapeutics
2.	Analgesia
3.	Vagus Nerve Stimulation
4.	Vagotomy
5.	Ovariectomy (Oophorectomy)